Market Cap 1.46B
Revenue (ttm) 7.02M
Net Income (ttm) -157.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,248.72%
Debt to Equity Ratio 0.00
Volume 1,201,700
Avg Vol 1,165,118
Day's Range N/A - N/A
Shares Out 66.41M
Stochastic %K 26%
Beta 1.22
Analysts Strong Sell
Price Target $55.69

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibit...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 200 7500
Fax: 908 454 1911
Address:
Perryville III Building, Suite 220 53 Frontage Road, Hampton, United States
Quantumup
Quantumup Aug. 25 at 12:32 PM
Guggenheim⬆️the PT on $COGT to $20 from $17 and reiterated at a Buy. $PFE $NVS BMPC - $SNY $CLDX DCPH - OPHLY SNDX Guggenheim said in its note:
0 · Reply
MatrixMomentum
MatrixMomentum Aug. 23 at 9:18 AM
$CLDX Celldex Therapeutics Inc is a clinical stage biotech with oncology pipeline and data milestones
1 · Reply
Steve1545
Steve1545 Aug. 21 at 2:07 PM
4 · Reply
anachartanalyst
anachartanalyst Aug. 20 at 7:02 PM
$CLDX https://anachart.com/wp-content/uploads/ana_temp/1755716531_soc-img.jpg
0 · Reply
jheerdink
jheerdink Aug. 20 at 5:15 PM
Celldex $CLDX Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - Profound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE https://finance.yahoo.com/news/celldex-reports-results-phase-2-200100891.html Now check out $EPRX Eupraxia Pharmaceuticals and their EOE program where they have announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis (“EoE”). Dr. James A. Helliwell, Director and Chief Executive Officer of Eupraxia. “Recent data updates support the potential of EP-104GI as a durable treatment option. In the most recent data update, all three patients demonstrated a sustained or improved treatment outcome after nine months of therapy. We look forward to announcing more results from the Phase 1b/2a portion of the RESOLVE trial in October."
0 · Reply
lucabrix
lucabrix Aug. 20 at 3:13 PM
$CLDX Eosinophilic Esophagitis is a global word market evaluated 0.46B$ for 2034, nothing compared Brazo size!
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 20 at 2:24 PM
$CLDX Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
0 · Reply
Steve1545
Steve1545 Aug. 20 at 2:11 PM
$CLDX scooped up 10 more
0 · Reply
JarvisFlow
JarvisFlow Aug. 20 at 1:55 PM
Canaccord Genuity has adjusted their stance on Celldex Therapeutics ( $CLDX ), setting the rating to Buy with a target price of 64 → 62.
0 · Reply
free2dream
free2dream Aug. 20 at 1:38 PM
$CLDX this was $580 per share
0 · Reply
Latest News on CLDX
Celldex Therapeutics: Rising High, With Room For Further Growth

May 10, 2024, 10:44 AM EDT - 1 year ago

Celldex Therapeutics: Rising High, With Room For Further Growth


MoneyShow's Best Investment Ideas For 2024: Part 2

Jan 26, 2024, 5:30 PM EST - 1 year ago

MoneyShow's Best Investment Ideas For 2024: Part 2

ANET BAX BIP BLK BP CCJ CSTE


Quantumup
Quantumup Aug. 25 at 12:32 PM
Guggenheim⬆️the PT on $COGT to $20 from $17 and reiterated at a Buy. $PFE $NVS BMPC - $SNY $CLDX DCPH - OPHLY SNDX Guggenheim said in its note:
0 · Reply
MatrixMomentum
MatrixMomentum Aug. 23 at 9:18 AM
$CLDX Celldex Therapeutics Inc is a clinical stage biotech with oncology pipeline and data milestones
1 · Reply
Steve1545
Steve1545 Aug. 21 at 2:07 PM
4 · Reply
anachartanalyst
anachartanalyst Aug. 20 at 7:02 PM
$CLDX https://anachart.com/wp-content/uploads/ana_temp/1755716531_soc-img.jpg
0 · Reply
jheerdink
jheerdink Aug. 20 at 5:15 PM
Celldex $CLDX Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - Profound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE https://finance.yahoo.com/news/celldex-reports-results-phase-2-200100891.html Now check out $EPRX Eupraxia Pharmaceuticals and their EOE program where they have announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis (“EoE”). Dr. James A. Helliwell, Director and Chief Executive Officer of Eupraxia. “Recent data updates support the potential of EP-104GI as a durable treatment option. In the most recent data update, all three patients demonstrated a sustained or improved treatment outcome after nine months of therapy. We look forward to announcing more results from the Phase 1b/2a portion of the RESOLVE trial in October."
0 · Reply
lucabrix
lucabrix Aug. 20 at 3:13 PM
$CLDX Eosinophilic Esophagitis is a global word market evaluated 0.46B$ for 2034, nothing compared Brazo size!
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 20 at 2:24 PM
$CLDX Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
0 · Reply
Steve1545
Steve1545 Aug. 20 at 2:11 PM
$CLDX scooped up 10 more
0 · Reply
JarvisFlow
JarvisFlow Aug. 20 at 1:55 PM
Canaccord Genuity has adjusted their stance on Celldex Therapeutics ( $CLDX ), setting the rating to Buy with a target price of 64 → 62.
0 · Reply
free2dream
free2dream Aug. 20 at 1:38 PM
$CLDX this was $580 per share
0 · Reply
OpenOutcrier
OpenOutcrier Aug. 20 at 12:34 PM
$CLDX (-9.9% pre) Celldex discontinues barzolvolimab development for eosinophilic esophagitis https://ooc.bz/l/74562
0 · Reply
Steve1545
Steve1545 Aug. 20 at 12:34 PM
$CLDX not much volume. Orchestrated sell off by pt.72 and Cohen most likely after they bid it up last week to exercise their $22.5 calls. Don’t make me t something it’s not. EoE not that important. CSU and AD can still make this 5-10x more valuable. HODL
0 · Reply
BPharmCatalyst
BPharmCatalyst Aug. 20 at 12:12 PM
$NVNO received an FDA not-approvable letter for its VenoValve PMA, citing insufficient evidence of benefit-risk despite improvements in clinical scores and raising safety concerns tied to the surgical procedure. The company is evaluating options, including a potential resubmission or appeal, while shifting its focus toward its non-surgical enVVe valve. $CLDX $CTSO $RCKT $ALC See More Pre-market Movers 👇 https://www.biopharmcatalyst.com/news/2025/enveno-nvno-not-approvable-letter-celldex-cldx-phase-2-data
0 · Reply
JarvisFlow
JarvisFlow Aug. 20 at 11:00 AM
HC Wainwright & Co. has adjusted their stance on Celldex Therapeutics ( $CLDX ), setting the rating to Buy with a target price of 50 → 42.
0 · Reply
FactsPlease99
FactsPlease99 Aug. 20 at 9:53 AM
$CLDX yikes….Not sure I would buy a falling knife. This could get messy under $19. CLDX never fails to disappoint. Been there motto for the last 10 years of failed trials. Lol
2 · Reply
StocktwitsNews
StocktwitsNews Aug. 20 at 1:50 AM
Why Are Celldex Shares Tumbling After Hours? $CLDX https://stocktwits.com/news/equity/markets/why-are-celldex-shares-tumbling-after-hours/chsieroRdWg
0 · Reply
DonCorleone77
DonCorleone77 Aug. 20 at 12:08 AM
$FLNT $LZB $JHX $TOL $CLDX Feel free to follow me for pre-market and after-hours movers every day. AFTER-HOURS MOVERS: Currently Higher After Earnings: -- Fluent (FLNT) up 20.6% Currently Lower After Earnings: -- James Hardie (JHX) down 26.5% -- La-Z-Boy (LZB) down 23.6% -- Alcon (ALC) down 6.8% -- ZTO Express (ZTO) down 5.7% -- Jack Henry & Associates (JKHY) down 2.3% -- Toll Brothers (TOL) down 1.4% Currently Also Lower: -- Celldex (CLDX) down 14.3% after barzolvolimab study update
0 · Reply
DonCorleone77
DonCorleone77 Aug. 19 at 11:59 PM
$CLDX Celldex down over 12% after barzolvolimab study update
0 · Reply
TheGunnerAB
TheGunnerAB Aug. 19 at 9:50 PM
$CLDX Major Investors are in for CSU as in Chronic Spontaneous Uticaria. Not for EoE. The company is in phase 3 after amazing results in phase 2. Much better than the SOC. CSU is a big market. The current market leader Zolair had over $4B revenue in 2024.
0 · Reply
RonIsWrong
RonIsWrong Aug. 19 at 9:37 PM
$CLDX Celldex Discontinues Barzolvolimab Development in Eosinophilic Esophagitis; Shares Fall After Hours -- Celldex Therapeutics(CLDX) said Tuesday it will not advance development of barzolvolimab in eosinophilic esophagitis after topline results from a phase 2 study showed the drug met its primary endpoint, but the mast cell depletion observed did not result in clinical improvement. The trial met the primary endpoint of absolute change in peak esophageal intraepithelial mast cell count at week 12, with barzolvolimab producing profound mast cell depletion compared to placebo. However, the company said the reduction did not result in an improvement in eosinophilic esophagitis symptoms or endoscopic assessment of disease activity versus placebo. Celldex said barzolvolimab maintained a favorable safety profile, consistent with previous studies. The company said it will not pursue the therapy in eosinophilic esophagitis but continues to advance development in other indications, including spontaneous urticaria, atopic dermatitis, and prurigo nodularis. The company's shares were down more than 15% in after-hours activity.
1 · Reply
lucabrix
lucabrix Aug. 19 at 8:36 PM
$CLDX The safety profile at the 300 mg Q4 weekly dosing remains favorable, consistent with previous studies. This is important as barzolvolimab continues development in multiple other indications including two Phase 3 studies in chronic spontaneous urticaria and Phase 2 studies in atopic dermatitis and prurigo nodularis. The company also plans to initiate a Phase 3 program in inducible urticaria. From a pipeline perspective, while the EoE setback is disappointing, the strong mechanistic data showing GI tract mast cell depletion validates pursuing other gastrointestinal conditions where mast cells have stronger evidence as disease drivers. The company maintains a deep pipeline of KIT- and SCF-targeting candidates that can leverage this mechanism in multiple indications.
0 · Reply
lucabrix
lucabrix Aug. 19 at 8:35 PM
$CLDX While the trial successfully met its primary endpoint by demonstrating profound depletion of mast cells in the esophagus (absolute change of -36.0 from baseline vs -2.7 for placebo, p<0.0001), this biological activity failed to translate into meaningful clinical improvements. The drug showed no significant benefit over placebo in key measures including dysphagia symptoms (p=0.33), endoscopic scoring (p=0.95), or reduction in eosinophil infiltration (p=0.57). These results provide valuable scientific insight by clearly demonstrating that mast cells are not primary drivers in EoE pathogenesis, contrary to previous hypotheses. This represents an important contribution to understanding this difficult-to-treat condition, but unfortunately means Celldex will discontinue development for this indication.
0 · Reply